Dec 06, 2021 / 01:00PM GMT
Operator
Greetings, and welcome to the Aeglea BioTherapeutics PEACE Phase III Topline Study Results. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Kelly Boothe, Head of Corporate Communications and Investor Relations for Aeglea BioTherapeutics. Thank you. You may begin.
Kelly Boothe - Aeglea BioTherapeutics, Inc. - Senior Director of Corporate Communications & IR
Thank you, operator, and good morning, everyone. Joining me on today's call to discuss the PEACE Phase III topline results are Dr. Anthony Quinn, Chief Executive Officer; Dr. Eric Bradford, Chief Development Officer; Michael Hanley, Chief Commercial Officer; Dr. Leslie Sloan, Chief Operating Officer; and Jonathan Alspaugh, Chief Financial Officer.
The Form 8-K with our press release was filed this morning and is available on the SEC's EDGAR system and on our website. I would like to remind you that various remarks that we make on this call include forward-looking statements for the purposes of the safe harbor
Aeglea Bio Therapeutics Inc Report Phase 3 Topline Results of Pegzilarginase in Patients with Arginase 1 Deficiency Call Transcript
Dec 06, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers